BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sivilia S, Lorenzini L, Giuliani A, Gusciglio M, Fernandez M, Baldassarro VA, Mangano C, Ferraro L, Pietrini V, Baroc MF, Viscomi AR, Ottonello S, Villetti G, Imbimbo BP, Calzà L, Giardino L. Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC Neurosci 2013;14:44. [PMID: 23560952 DOI: 10.1186/1471-2202-14-44] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Hur JY. γ-Secretase in Alzheimer's disease. Exp Mol Med 2022;54:433-46. [PMID: 35396575 DOI: 10.1038/s12276-022-00754-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
2 Fronza MG, Sacramento M, Alves D, Praticò D, Savegnago L. 1-(7-Chloroquinolin-4-yl)-N-(4-Methoxybenzyl)-5-Methyl-1H-1,2, 3-Triazole-4- carboxamide Reduces Aβ Formation and Tau Phosphorylation in Cellular Models of Alzheimer's Disease. Neurochem Res 2022. [PMID: 35165799 DOI: 10.1007/s11064-021-03514-8] [Reference Citation Analysis]
3 Wen J, Liu D, Zhao L. Small molecules targeting γ-secretase and their potential biological applications. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Xu Y, Wang C, Wey HY, Liang Y, Chen Z, Choi SH, Ran C, Rynearson KD, Bernales DR, Koegel RE, Fiedler SA, Striar R, Wagner SL, Tanzi RE, Zhang C. Molecular imaging of Alzheimer's disease-related gamma-secretase in mice and nonhuman primates. J Exp Med 2020;217:e20182266. [PMID: 32936886 DOI: 10.1084/jem.20182266] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
5 Soto-Rojas LO, Pacheco-Herrero M, Martínez-Gómez PA, Campa-Córdoba BB, Apátiga-Pérez R, Villegas-Rojas MM, Harrington CR, de la Cruz F, Garcés-Ramírez L, Luna-Muñoz J. The Neurovascular Unit Dysfunction in Alzheimer's Disease. Int J Mol Sci 2021;22:2022. [PMID: 33670754 DOI: 10.3390/ijms22042022] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 25.0] [Reference Citation Analysis]
6 Pinheiro L, Faustino C. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease. Curr Alzheimer Res 2019;16:418-52. [PMID: 30907320 DOI: 10.2174/1567205016666190321163438] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 21.5] [Reference Citation Analysis]
7 Trambauer J, Fukumori A, Steiner H. Pathogenic Aβ generation in familial Alzheimer’s disease: novel mechanistic insights and therapeutic implications. Current Opinion in Neurobiology 2020;61:73-81. [DOI: 10.1016/j.conb.2020.01.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
8 Baldassarro VA, Bighinati A, Sannia M, Giardino L, Calzà L. Brain susceptibility to hypoxia/hypoxemia and metabolic dysfunction in Alzheimer's disease. Genetics, Neurology, Behavior, and Diet in Dementia 2020. [DOI: 10.1016/b978-0-12-815868-5.00026-8] [Reference Citation Analysis]
9 Fronza MG, Baldinotti R, Martins MC, Goldani B, Dalberto BT, Kremer FS, Begnini K, Pinto LDS, Lenardão EJ, Seixas FK, Collares T, Alves D, Savegnago L. Rational design, cognition and neuropathology evaluation of QTC-4-MeOBnE in a streptozotocin-induced mouse model of sporadic Alzheimer's disease. Sci Rep 2019;9:7276. [PMID: 31086208 DOI: 10.1038/s41598-019-43532-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
10 Pedrini S, Morici M, Martins RN. Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases). Neurodegeneration and Alzheimer's Disease 2019. [DOI: 10.1002/9781119356752.ch14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Hollas MA, Ben Aissa M, Lee SH, Gordon-Blake JM, Thatcher GRJ. Pharmacological manipulation of cGMP and NO/cGMP in CNS drug discovery. Nitric Oxide 2019;82:59-74. [PMID: 30394348 DOI: 10.1016/j.niox.2018.10.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
12 Piton M, Hirtz C, Desmetz C, Milhau J, Lajoix AD, Bennys K, Lehmann S, Gabelle A. Alzheimer’s Disease: Advances in Drug Development. JAD 2018;65:3-13. [DOI: 10.3233/jad-180145] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 8.5] [Reference Citation Analysis]
13 Baheti K, Kale M. Methodologies Related to Computational Models in View of Developing Anti-Alzheimer Drugs: An Overview. Curr Drug Discov Technol 2019;16:66-73. [PMID: 29663890 DOI: 10.2174/1570163815666180417120833] [Reference Citation Analysis]
14 Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, Schneider LS, Welikovitch LA, Woodcock J, Baldacci F, Lista S. Precision pharmacology for Alzheimer’s disease. Pharmacological Research 2018;130:331-65. [DOI: 10.1016/j.phrs.2018.02.014] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 16.3] [Reference Citation Analysis]
15 Sogorb-Esteve A, García-Ayllón MS, Llansola M, Felipo V, Blennow K, Sáez-Valero J. Inhibition of γ-Secretase Leads to an Increase in Presenilin-1. Mol Neurobiol 2018;55:5047-58. [PMID: 28815510 DOI: 10.1007/s12035-017-0705-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
16 Acero G, Nava Catorce M, González-mendoza R, Meraz-rodríguez MA, Hernández-zimbron LF, González-salinas R, Gevorkian G. Sodium thiosulphate attenuates brain inflammation induced by systemic lipopolysaccharide administration in C57BL/6J mice. Inflammopharmacol 2017;25:585-93. [DOI: 10.1007/s10787-017-0355-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
17 Baldassarro VA, Marchesini A, Giardino L, Calzà L. Vulnerability of primary neurons derived from Tg2576 Alzheimer mice to oxygen and glucose deprivation: role of intraneuronal amyloid-β accumulation and astrocytes. Dis Model Mech 2017;10:671-8. [PMID: 28237964 DOI: 10.1242/dmm.028001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
18 Porrini V, Sarnico I, Benarese M, Branca C, Mota M, Lanzillotta A, Bellucci A, Parrella E, Faggi L, Spano P, Imbimbo BP, Pizzi M. Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation. Int J Mol Sci 2017;18:E184. [PMID: 28106772 DOI: 10.3390/ijms18010184] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
19 Hall A, Velter A. Targeting γ-Secretase for the Treatment of Alzheimer’s Disease. Comprehensive Medicinal Chemistry III. Elsevier; 2017. pp. 280-325. [DOI: 10.1016/b978-0-12-409547-2.13789-8] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
20 Ruthirakuhan M, Herrmann N, Suridjan I, Abraham EH, Farber I, Lanctôt KL. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease. Expert Opinion on Pharmacotherapy 2016;17:2417-29. [DOI: 10.1080/14656566.2016.1258060] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
21 Lorenzini L, Giuliani A, Sivilia S, Baldassarro VA, Fernandez M, Lotti Margotti M, Giardino L, Fontani V, Rinaldi S, Calzà L. REAC technology modifies pathological neuroinflammation and motor behaviour in an Alzheimer's disease mouse model. Sci Rep 2016;6:35719. [PMID: 27775040 DOI: 10.1038/srep35719] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
22 Rubagotti S, Croci S, Ferrari E, Iori M, Capponi PC, Lorenzini L, Calzà L, Versari A, Asti M. Affinity of (nat/68)Ga-Labelled Curcumin and Curcuminoid Complexes for β-Amyloid Plaques: Towards the Development of New Metal-Curcumin Based Radiotracers. Int J Mol Sci 2016;17:E1480. [PMID: 27608011 DOI: 10.3390/ijms17091480] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
23 Nava Catorce M, Acero G, Pedraza-chaverri J, Fragoso G, Govezensky T, Gevorkian G. Alpha-mangostin attenuates brain inflammation induced by peripheral lipopolysaccharide administration in C57BL/6J mice. Journal of Neuroimmunology 2016;297:20-7. [DOI: 10.1016/j.jneuroim.2016.05.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
24 Cui L, Cai Y, Cheng W, Liu G, Zhao J, Cao H, Tao H, Wang Y, Yin M, Liu T, Liu Y, Huang P, Liu Z, Li K, Zhao B. A Novel, Multi-Target Natural Drug Candidate, Matrine, Improves Cognitive Deficits in Alzheimer's Disease Transgenic Mice by Inhibiting Aβ Aggregation and Blocking the RAGE/Aβ Axis. Mol Neurobiol 2017;54:1939-52. [PMID: 26899576 DOI: 10.1007/s12035-016-9783-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
25 Leggio GM, Catania MV, Puzzo D, Spatuzza M, Pellitteri R, Gulisano W, Torrisi SA, Giurdanella G, Piazza C, Impellizzeri AR, Gozzo L, Navarria A, Bucolo C, Nicoletti F, Palmeri A, Salomone S, Copani A, Caraci F, Drago F. The antineoplastic drug flavopiridol reverses memory impairment induced by Amyloid-ß1-42 oligomers in mice. Pharmacol Res 2016;106:10-20. [PMID: 26875816 DOI: 10.1016/j.phrs.2016.02.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
26 Awasthi M, Singh S, Pandey VP, Dwivedi UN. Alzheimer's disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products. Journal of the Neurological Sciences 2016;361:256-71. [DOI: 10.1016/j.jns.2016.01.008] [Cited by in Crossref: 86] [Cited by in F6Publishing: 88] [Article Influence: 14.3] [Reference Citation Analysis]
27 Golde T, Lessard C, Ran Y. Therapeutic Targeting of Aβ42. Developing Therapeutics for Alzheimer's Disease 2016. [DOI: 10.1016/b978-0-12-802173-6.00005-8] [Reference Citation Analysis]
28 Porrini V, Lanzillotta A, Branca C, Benarese M, Parrella E, Lorenzini L, Calzà L, Flaibani R, Spano P, Imbimbo B, Pizzi M. CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid. Neuroscience 2015;302:112-20. [DOI: 10.1016/j.neuroscience.2014.10.029] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
29 Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16:358-372. [PMID: 25991443 DOI: 10.1038/nrn3880] [Cited by in Crossref: 1284] [Cited by in F6Publishing: 1329] [Article Influence: 183.4] [Reference Citation Analysis]
30 Brendel M, Jaworska A, Herms J, Trambauer J, Rötzer C, Gildehaus FJ, Carlsen J, Cumming P, Bylund J, Luebbers T, Bartenstein P, Steiner H, Haass C, Baumann K, Rominger A. Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment. Mol Psychiatry 2015;20:1179-87. [PMID: 26055427 DOI: 10.1038/mp.2015.74] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
31 Grayson B, Leger M, Piercy C, Adamson L, Harte M, Neill JC. Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents. Behavioural Brain Research 2015;285:176-93. [DOI: 10.1016/j.bbr.2014.10.025] [Cited by in Crossref: 134] [Cited by in F6Publishing: 139] [Article Influence: 19.1] [Reference Citation Analysis]
32 Li C, Zug C, Qu H, Schluesener H, Zhang Z. Hesperidin ameliorates behavioral impairments and neuropathology of transgenic APP/PS1 mice. Behavioural Brain Research 2015;281:32-42. [DOI: 10.1016/j.bbr.2014.12.012] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 7.6] [Reference Citation Analysis]
33 Rinaldi S, Calzà L, Giardino L, Biella GE, Zippo AG, Fontani V. Radio electric asymmetric conveyer: a novel neuromodulation technology in Alzheimer's and other neurodegenerative diseases. Front Psychiatry 2015;6:22. [PMID: 25741289 DOI: 10.3389/fpsyt.2015.00022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
34 Farr SA, Erickson MA, Niehoff ML, Banks WA, Morley JE. Central and peripheral administration of antisense oligonucleotide targeting amyloid-β protein precursor improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (AβPPswe) mice. J Alzheimers Dis 2014;40:1005-16. [PMID: 24577464 DOI: 10.3233/JAD-131883] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
35 Seneci P. Chemical Modulators of Protein Misfolding, Neurodegeneration and Tau. Chemical Modulators of Protein Misfolding and Neurodegenerative Disease 2015. [DOI: 10.1016/b978-0-12-801944-3.00001-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Schafer MJ, Alldred MJ, Lee SH, Calhoun ME, Petkova E, Mathews PM, Ginsberg SD. Reduction of β-amyloid and γ-secretase by calorie restriction in female Tg2576 mice. Neurobiol Aging 2015;36:1293-302. [PMID: 25556162 DOI: 10.1016/j.neurobiolaging.2014.10.043] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 7.6] [Reference Citation Analysis]
37 McGeer PL, McGeer EG. Targeting microglia for the treatment of Alzheimer's disease. Expert Opin Ther Targets. 2015;19:497-506. [PMID: 25435348 DOI: 10.1517/14728222.2014.988707] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 7.6] [Reference Citation Analysis]
38 Cheng YL, Choi Y, Sobey CG, Arumugam TV, Jo DG. Emerging roles of the γ-secretase-notch axis in inflammation. Pharmacol Ther 2015;147:80-90. [PMID: 25448038 DOI: 10.1016/j.pharmthera.2014.11.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
39 Hall A, Patel TR. γ-Secretase modulators: current status and future directions. Prog Med Chem 2014;53:101-45. [PMID: 24418609 DOI: 10.1016/B978-0-444-63380-4.00003-2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 12] [Article Influence: 4.9] [Reference Citation Analysis]
40 Jia Q, Deng Y, Qing H. Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials. Biomed Res Int 2014;2014:837157. [PMID: 25136630 DOI: 10.1155/2014/837157] [Cited by in Crossref: 40] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
41 Branca C, Sarnico I, Ruotolo R, Lanzillotta A, Viscomi AR, Benarese M, Porrini V, Lorenzini L, Calzà L, Imbimbo BP, Ottonello S, Pizzi M. Pharmacological targeting of the β-amyloid precursor protein intracellular domain. Sci Rep 2014;4:4618. [PMID: 24714650 DOI: 10.1038/srep04618] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
42 Beggiato S, Giuliani A, Sivilia S, Lorenzini L, Antonelli T, Imbimbo B, Giardino L, Calzà L, Ferraro L. CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice. Neuroscience 2014;266:13-22. [DOI: 10.1016/j.neuroscience.2014.01.065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
43 Mango D, Barbato G, Piccirilli S, Panico MB, Feligioni M, Schepisi C, Graziani M, Porrini V, Benarese M, Lanzillotta A, Pizzi M, Pieraccini S, Sironi M, Blandini F, Nicoletti F, Mercuri NB, Imbimbo BP, Nisticò R. Electrophysiological and metabolic effects of CHF5074 in the hippocampus: protection against in vitro ischemia. Pharmacol Res 2014;81:83-90. [PMID: 24630950 DOI: 10.1016/j.phrs.2014.02.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
44 Birch AM, Katsouri L, Sastre M. Modulation of inflammation in transgenic models of Alzheimer's disease. J Neuroinflammation 2014;11:25. [PMID: 24490742 DOI: 10.1186/1742-2094-11-25] [Cited by in Crossref: 88] [Cited by in F6Publishing: 89] [Article Influence: 11.0] [Reference Citation Analysis]
45 Pandian GN, Taylor RD, Junetha S, Saha A, Anandhakumar C, Vaijayanthi T, Sugiyama H. Alteration of epigenetic program to recover memory and alleviate neurodegeneration: prospects of multi-target molecules. Biomater Sci 2014;2:1043-56. [DOI: 10.1039/c4bm00068d] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
46 Baldassarro VA, Lizzo G, Paradisi M, Fernández M, Giardino L, Calzà L. Neural stem cells isolated from amyloid precursor protein-mutated mice for drug discovery. World J Stem Cells 2013; 5(4): 229-237 [PMID: 24179610 DOI: 10.4252/wjsc.v5.i4.229] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
47 Aprahamian I, Stella F, Forlenza OV. New treatment strategies for Alzheimer's disease: is there a hope? Indian J Med Res 2013;138:449-60. [PMID: 24434253] [Reference Citation Analysis]
48 Zhang ZY, Daniels R, Schluesener HJ. Oridonin ameliorates neuropathological changes and behavioural deficits in a mouse model of cerebral amyloidosis. J Cell Mol Med 2013;17:1566-76. [PMID: 24034629 DOI: 10.1111/jcmm.12124] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 4.8] [Reference Citation Analysis]
49 Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L. γ-Secretase inhibitors and modulators. Biochim Biophys Acta 2013;1828:2898-907. [PMID: 23791707 DOI: 10.1016/j.bbamem.2013.06.005] [Cited by in Crossref: 195] [Cited by in F6Publishing: 210] [Article Influence: 21.7] [Reference Citation Analysis]